The Safety, Tolerability, Pharmacokinetic, Pharmacodynamics and Food Effect Study of HEC96719 in Healthy Subjects
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
66
Part 2:Mulltiple doses up to 10 days
The Shanghai xuhui district central hospital
Shanghai, Shanghai Municipality, China
Safety and Tolerability of HEC96719 by Assessment of the Number of Adverse Events
To investigate the safety and tolerability of HEC96719 by assessment of AEs (non-serious and serious) following administration of oral solution in MAD
Time frame: up to 17 days
Cmax
Maximum Plasma Concentration(Cmax)of HEC96719
Time frame: up to 96 hours
AUC
Area Under the Curve(AUC) of HEC96719
Time frame: up to 96 hours
Tmax
Maximum Peak Time(Tmax) of HEC96719
Time frame: up to 96 hours
T1/2
Maximum Peak Time(Tmax) of HEC96719
Time frame: up to 96 hours
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.